Posted by Michael Wonder on 02 Jun 2025
RSV prophylaxis with nirsevimab: benefits for healthy children in the first RSV season
2 June 2025 - Children immunised with the antibody nirsevimab are significantly less likely to develop RSV-related lower respiratory tract infections.
Prophylaxis with nirsevimab in the first RSV season has exclusively positive effects: children without an increased risk of RSV disease who are immunised with it develop significantly less (severe) RSV-related lower respiratory tract infections. Therefore, IQWiG sees evidence of a considerable additional clinical benefit.
